Evidence map›Paper›PMID 38352109›Full record

ReviewCureus2024

Dermatological Manifestations in Patients With Chronic Kidney Disease: A Review.

David Arriaga Escamilla, Alisha Lakhani, Sneha Antony, Karla N Salazar Villegas, Manasvi Gupta, Parameswaran Ramnath, María Isabel Murillo Pineda, Alexandra Bedor, Douglas Banegas, Ernesto Calderon Martinez

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. CutaneousInternational journal of molecular sciences · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 6 countries.

David Arriaga EscamillaInternal Medicine, Universidad Justo Sierra, Mexico City, MEX.
Alisha LakhaniMedicine, Research MD, Vadodara, IND.
Sneha AntonyPharmacology, K S Hegde Medical Academy, Mangalore, IND.
Karla N Salazar VillegasDermatology, Hospital General de Zona 29, Ciudad de Mexico, MEX.
Manasvi GuptaGeneral Practice, Jawaharlal Nehru Medical College, Aligarh, IND.
Parameswaran RamnathMedicine, Jonelta Foundation School of Medicine, Manila, PHL.
María Isabel Murillo PinedaPrimary Care, Universidad Católica de Honduras, Tegucigalpa, HND.
Alexandra BedorInternal Medicine, Instituto Salvadoreño del Seguro Social, San Salvador, SLV.
Douglas BanegasGeneral Medicine, Universidad Nacional Autonoma de Honduras, San Pedro Sula, HND.
Ernesto Calderon MartinezDigital Health, Universidad Nacional Autónoma de México, Ciudad de Mexico, MEX.
Fetal Medicine Foundation · GBHospital General De Zona · MXJawaharlal Nehru Medical College Hospital · INJusto Sierra University · MXK S Hegde Medical Academy · INNational Autonomous University of Honduras · HNShantou University · CNUniversidad Autónoma de la Ciudad de México · MXUniversidad Católica de Honduras Nuestra Señora Reina de la Paz · HNUniversidad del Salvador · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a progressive disease and has multiple clinical manifestations; when CKD reaches the end stage, at least one cutaneous manifestation appears due to some increased toxin levels or a constant proinflammatory state. Nonspecific manifestations include pruritus, xerosis, pigmentation disorders, acquired ichthyosis, purpuric spots, and nail disorders. Some specific manifestations are bullous dermatoses, acquired perforating dermatoses (APD), eruptive xanthoma, access site infections, calcifying disorders, and nephrogenic systemic fibrosis (NSF). All these cutaneous changes negatively impact patients; early recognition and diagnosis of these dermatoses will make a difference in their quality of treatment. Exploring a patient's skin is fundamental to suspect some diseases and increased toxin levels; pruritus occurs when uremic toxins are raised, and nail disorders are associated with hypoalbuminemia. This review provides the clinician with information on the clinical manifestations that occur in CKD, including epidemiology, pathophysiology, clinical manifestations, diagnosis, histopathology, treatment, and life impact of the dermatoses in CKD.

Indexed as

access site infectionsacquired perforating dermatosescaciphylaxischronic kidney diseasedermatosesnephrogenic systemic fibrosisporphyria cutanea tardaprurituspseudoporphyriaxerosis

Identifiers

PMID38352109
PMCPMC10863542
OpenAlexW4390858467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.